Springer is delighted to announce a new memo inOncology SPECIAL ISSUE congress report in collaboration with CSCO!
2017 CSCO annual meeting memo inOncology congress report
The 20th Chinese Society of Clinical Oncology (CSCO) annual meeting took place in Xiamen from September 26th to 30th, 2017. This congress report summarises the latest findings on lung cancer care that were presented at the congress, including the latest CSCO guidelines for NSCLC, how best to diagnose and treat EGFR-mutated NSCLC, how best to treat lung cancer patients with brain metastases, treatment options for lung squamous cell carcinoma, and the response to immunotherapy.
- Guidelines for the treatment of NSCLC in China: progress and controversies
- Diagnosis of EGFR-mutated NSCLC: from guidelines to reality
- Different therapies for treatment of squamous cell carcinoma
- Optimal strategy for the treatment of EGFR-mutant lung cancer
- New insights into the treatment of ALK-mutant-positive NSCLC patients
- Determination of clinical responses to immunotherapy
- Combination of targeted therapy with radiotherapy for treatment of brain metastasis
- Full Report (English)
- Full Report (Mandarin)
Expert interviews at CSCO annual meeting
Caicun Zhou discusses NSCLC care in China, and the use of molecular targeted agents
Shun Lu discusses the recent clinical trial data for EGFR targeted agents and how this will shape clinical practice, as well as the need for solid clinical trial data revealing how the sequencing of EGFR directed agents affects survival